Tremelimumab-actl (Imjudo) is a monoclonal antibody directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which is one of the checkpoints that regulates the immune system. Blocking the “shut off” checkpoint keeps the immune cells within the tumor active.
The drug is indicated for the treatment of patients with hepatocellular carcinoma and non-small cell lung cancer.